98%
921
2 minutes
20
Background: Before April 2022, monkeypox virus infection in humans was seldom reported outside African regions where it is endemic. Currently, cases are occurring worldwide. Transmission, risk factors, clinical presentation, and outcomes of infection are poorly defined.
Methods: We formed an international collaborative group of clinicians who contributed to an international case series to describe the presentation, clinical course, and outcomes of polymerase-chain-reaction-confirmed monkeypox virus infections.
Results: We report 528 infections diagnosed between April 27 and June 24, 2022, at 43 sites in 16 countries. Overall, 98% of the persons with infection were gay or bisexual men, 75% were White, and 41% had human immunodeficiency virus infection; the median age was 38 years. Transmission was suspected to have occurred through sexual activity in 95% of the persons with infection. In this case series, 95% of the persons presented with a rash (with 64% having ≤10 lesions), 73% had anogenital lesions, and 41% had mucosal lesions (with 54 having a single genital lesion). Common systemic features preceding the rash included fever (62%), lethargy (41%), myalgia (31%), and headache (27%); lymphadenopathy was also common (reported in 56%). Concomitant sexually transmitted infections were reported in 109 of 377 persons (29%) who were tested. Among the 23 persons with a clear exposure history, the median incubation period was 7 days (range, 3 to 20). Monkeypox virus DNA was detected in 29 of the 32 persons in whom seminal fluid was analyzed. Antiviral treatment was given to 5% of the persons overall, and 70 (13%) were hospitalized; the reasons for hospitalization were pain management, mostly for severe anorectal pain (21 persons); soft-tissue superinfection (18); pharyngitis limiting oral intake (5); eye lesions (2); acute kidney injury (2); myocarditis (2); and infection-control purposes (13). No deaths were reported.
Conclusions: In this case series, monkeypox manifested with a variety of dermatologic and systemic clinical findings. The simultaneous identification of cases outside areas where monkeypox has traditionally been endemic highlights the need for rapid identification and diagnosis of cases to contain further community spread.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1056/NEJMoa2207323 | DOI Listing |
Eur J Clin Microbiol Infect Dis
September 2025
Department of Infectious and Tropical Diseases, Toulouse University Hospital, Toulouse, 31059 Cedex 9, France.
Purpose: This narrative review aims to provide an overview of current knowledge on mpox, emphasizing updated epidemiology and recent advances in treatment and prevention strategies, in light of the latest outbreaks.
Methods: We searched PubMed and Google Scholar for publications on 'Mpox' and 'Monkeypox' up to June 5, 2025. Grey literature from governmental and health agencies was also accessed for outbreak reports and guidelines where published evidence was unavailable.
J Infect Dis
September 2025
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
Utilising mpox case data from Burundi between August 2024 and April 2025, we calibrated a mathematical model to quantify the temporal trends of clade Ib monkeypox virus transmission. The model outputs indicated a declining overall transmission trend. Children aged 0-4 and 5-9 years were estimated to be at higher risk of infection compared to older age groups, while sexual contact was inferred to contribute up to 50% of the overall transmission.
View Article and Find Full Text PDFJ Infect Dis
September 2025
Biological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, Ontario, Canada.
Background: Tecovirimat (TPOXX) is an antiviral authorized for the treatment of mpox infections in Canada, but recent clinical trials found it has no impact on symptom duration.
Methods: We conducted a prospective cohort study of individuals diagnosed with mpox in Toronto, Canada. Skin lesion swabs were collected weekly to quantify infectious monkeypox virus (MPXV) shedding through cell culture.
Med Sci (Paris)
September 2025
UMI233 TransVIHMI (Recherches translationnelles sur le VIH et les maladies infectieuses), Université de Montpellier, IRD, INSERM Unité 1175, Montpellier, France.
For a long time neglected, the mpox virus has caused two public health emergency declarations by the World Health Organization in just two years. Rapid detection and characterization of the viral strains involved are crucial for better control of the disease. Recent work on viral genome sequencing in the Democratic Republic of the Congo (DRC) has shown the emergence in 2023 of clade Ib, with sustained human-to-human transmission and rapid spread to several other non-endemic neighboring countries, as well as outside Africa.
View Article and Find Full Text PDFJ Virol Methods
September 2025
British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:
In 2022, cases of Monkeypox virus (MPXV) in California contained a mutation in the TNF receptor gene (GR2G) that rendered the virus undetectable using a widely adopted public health diagnostic qPCR assay. This underscored the need for a dual-target PCR approach and prompted validation of a second target by the BCCDC Public Health Laboratory. In addition to the GR2G target validated in the original qPCR assay (and duplexed with the endogenous target human β-globin (HBG)), GP113 (OPG128) was identified and validated using both clinical samples and MPXV DNA controls.
View Article and Find Full Text PDF